Literature DB >> 15705631

Survival and safety of treatment with infliximab in the elderly population.

H Chevillotte-Maillard, P Ornetti, R Mistrih, C Sidot, J Dupuis, J-A Dellas, C Tavernier, J F Maillefert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15705631     DOI： 10.1093/rheumatology/keh562

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  19 in total

Review 1.  Elderly patients and inflammatory bowel disease.

Authors:  Danielle Nimmons; Jimmy K Limdi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

2.  How elderly rheumatoid arthritis patients respond at one year of treatment with certolizumab pegol.

Authors:  Vicenç Torrente-Segarra; Manuel Fernandez Prada; Rosa Expósito Moliner; Noemí Patricia Garrido Puñal; Amalia Sánchez-Andrade Fernández; José Ramón Lamua Riazuelo; Alejandro Olivé; Juan Víctor Tovar Beltrán
Journal:  Rheumatol Int       Date:  2018-11-24       Impact factor: 2.631

3.  Old-age inflammatory bowel disease onset: a different problem?

Authors:  Joaquin Hinojosa del Val
Journal:  World J Gastroenterol       Date:  2011-06-14       Impact factor: 5.742

4.  Does Older Age have an Impact on Rituximab Efficacy and Safety? Results from the NOR-DMARD Register.

Authors:  Pawel Mielnik; Joseph Sexton; Elisabeth Lie; Gunnstein Bakland; Liz P Loli; Eirik K Kristianslund; Erik Rødevand; Åse S Lexberg; Tore K Kvien
Journal:  Drugs Aging       Date:  2020-08       Impact factor: 3.923

Review 5.  Late-onset ankylosing spondylitis and spondylarthritis: an update on clinical manifestations, differential diagnosis and pharmacological therapies.

Authors:  Eric Toussirot
Journal:  Drugs Aging       Date:  2010-07-01       Impact factor: 3.923

Review 6.  Diagnosis and Management of Late-Onset Spondyloarthritis: Implications of Treat-to-Target Recommendations.

Authors:  Éric Toussirot
Journal:  Drugs Aging       Date:  2015-07       Impact factor: 3.923

7.  74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis.

Authors:  Isabelle Delabaye; Filip De Keyser
Journal:  Arthritis Res Ther       Date:  2010-06-22       Impact factor: 5.156

Review 8.  Elderly-onset sarcoidosis: prevalence, clinical course, and treatment.

Authors:  Yvan Jamilloux; Marc Bonnefoy; Dominique Valeyre; Loig Varron; Christiane Broussolle; Pascal Sève
Journal:  Drugs Aging       Date:  2013-12       Impact factor: 3.923

9.  Patterns of biologic agent use in older males with inflammatory diseases: an institution-focused, observational post-marketing study.

Authors:  Suong Tran; Roderick S Hooker; Daisha J Cipher; Andreas Reimold
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 10.  Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis.

Authors:  Alejandro Díaz-Borjón
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.